SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Clinical Trials
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Carey, V. J
Right arrow Articles by Appel, L. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carey, V. J
Right arrow Articles by Appel, L. J
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cholesterol
*Clinical Trials
*Diets
*Heart Disease in Women
*Heart Diseases
*High Blood Pressure
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Rationale and design of the Optimal Macro-Nutrient Intake Heart Trial to Prevent Heart Disease (OMNI-Heart)

Vincent J Carey

Channing Laboratory, Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA vincent.carey{at}channing.harvard.edu

Louise Bishop

Brigham and Women's Hospital, Boston, MA, USA

Jeanne Charleston

Johns Hopkins University Bloomberg School of Public Health, 1849 Gwynn Oak Avenue Suite 1, Baltimore, MD, USA

Paul Conlin

Brigham and Women's Hospital, Boston, MA, USA

Tate Erlinger

Welch Center for Prevention, Epidemiology and International Health, Johns Hopkins University, Baltimore, MD, USA

Nancy Laranjo

Channing Laboratory, Harvard Medical School, Boston, MA, USA

Phyllis McCarron

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Edgar Miller

Welch Center for Prevention, Epidemiology and International Health, Johns Hopkins University, Baltimore, MD, USA

Bernard Rosner

Channing Laboratory, Harvard Medical School, Boston, MA, USA

Janis Swain

Brigham and Women's Hospital, Boston, MA, USA

Frank M Sacks

Dept of Nutrition, Harvard School of Public Health, Boston, MA, USA

Lawrence J Appel

Welch Center for Prevention, Epidemiology and International Health, Johns Hopkins University, Baltimore, MD, USA

Background The DASH (Dietary Approaches to Stop Hypertension) diet is a carbohydrate-rich, reduced-fat diet that lowers blood pressure (BP) and LDL-cholesterol. Whether partial replacement of some carbohydrate (C) with either protein (P) or unsaturated fat (U) can further improve these and other cardiovascular (CVD) risk factors is unknown.

Methods OmniHeart is a randomized, three-period, crossover feeding study designed to compare the effects on BP and blood lipids of a carbohydrate-rich diet (CARB, similar to the DASH diet) with a diet rich in protein (PROT, predominantly from nonmeat sources) and a diet rich in unsaturated fat (UNSAT, predominantly monounsaturated). Throughout feeding (run in and the three intervention periods), participants are provided with all of their meals that meet the nutrient profile of their assigned diet. Calorie intake is adjusted to maintain weight. The target sample size is 160 (50% African-American). Participants are adults, aged 30 or older, with prehypertension or Stage 1 hypertension (systolic BP 120–159 or diastolic BP 80–99 mmHg). The primary outcome variables are systolic BP and LDL-cholesterol. Secondary outcomes are diastolic BP, HDL-cholesterol, and triglycerides. Other outcome variables are total cholesterol, apolipoproteins VLDL-apoB, VLDL-apoCIII, apolipoprotein B, non-HDL cholesterol, and lipoprotein(a), and insulin resistance, as measured by Homeostasis Model Assessment (HOMA).

Conclusions OMNI-Heart should advance our fundamental knowledge of the effects of diet on both traditional and emerging risk factors, and, in the process, guide policy makers, health care providers and the general public on the relative benefits of carbohydrate, protein, and unsaturated fat as a means to reduce CVD risk.

Clinical Trials, Vol. 2, No. 6, 529-537 (2005)
DOI: 10.1191/1740774505cn123oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am J EpidemiolHome page
J. M. Beasley, B. A. Ange, C. A. M. Anderson, E. R. Miller III, T. P. Erlinger, J. T. Holbrook, F. M. Sacks, and L. J. Appel
Associations Between Macronutrient Intake and Self-reported Appetite and Fasting Levels of Appetite Hormones: Results From the Optimal Macronutrient Intake Trial to Prevent Heart Disease
Am. J. Epidemiol., April 1, 2009; 169(7): 893 - 900.
[Abstract] [Full Text] [PDF]



Advertisement